CDKN2A loss, that promotes cell cycle progression by increasing CDK4/6 activity27, has been reported in therapy exposed BC metastases in different studies22,28, suggesting that this genetic event might contribute to endocrine resistance or tumour progression of metastatic BC. The gene discussed is CDK4; the disease is neoplasm.